The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase II study of pembrolizumab (P) alone versus pegilodecakin (PEG) in combination with P as first-line (1L) therapy in patients (pts) with stage IV non-small cell lung cancer (NSCLC) with high PD-L1 expression (CYPRESS 1).
 
David R. Spigel
Leadership - TriStar Centennial Medical Center
Consulting or Advisory Role - Aptitude Health (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Dracen (Inst); EMD Serono (Inst); Evelo Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Iksuda Therapeutics (Inst); Illumina (Inst); Merck (Inst); Molecular Templates (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Seagen (Inst); Takeda (Inst); TRIPTYCH Health Partners (Inst); TRM Oncology (Inst); Williams and Connolly (Inst)
Research Funding - Aeglea Biotherapeutics (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BIND Therapeutics (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celldex (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); GRAIL (Inst); ImClone Systems (Inst); Immunogen (Inst); Ipsen (Inst); Janssen Oncology (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Molecular Partners (Inst); Nektar (Inst); Neon Therapeutics (Inst); Novartis (Inst); Takeda (Inst); Transgene (Inst); University of Texas Southwestern Medical Center - Simmons Cancer Center (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Genentech; GlaxoSmithKline; Janssen Oncology; Merck; Novartis; Pfizer; Seagen; Spectrum Pharmaceuticals; Takeda
 
Merrill Kingman Shum
No Relationships to Disclose
 
Jeffrey Gary Schneider
Stock and Other Ownership Interests - Arvinas; Bristol-Myers Squibb; GlaxoSmithKline; Mirati Therapeutics; Novartis; Pfizer
Honoraria - Foundation Medicine
 
Robert M. Jotte
Honoraria - Bristol-Myers Squibb; Roche/Genentech
Speakers' Bureau - Bristol-Myers Squibb; Roche/Genentech
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche/Genentech
 
Jennifer L. Eisenstein
No Relationships to Disclose
 
Viralkumar K. Bhanderi
No Relationships to Disclose
 
Kartik Konduri
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim France; Takeda
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Takeda
 
Annie Hung
Employment - ARMO BioSciences; Lilly
Stock and Other Ownership Interests - ARMO BioSciences; Lilly
 
Rebecca R. Hozak
Employment - Lilly
Stock and Other Ownership Interests - Lilly
Patents, Royalties, Other Intellectual Property - Patent published and pending related to ramucirumab.
 
David Raymond Ferry
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Leena Gandhi
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Bo H. Chao
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Igor I. Rybkin
Consulting or Advisory Role - AstraZeneca